Bristol fusion startup Astral Systems has raised £23mn to scale the medical isotopes that cancer scans depend on. The Astral Systems £23M round backs a rare fusion company that already runs reactors and earns revenue.
Most fusion companies promise clean power in a decade or two. Astral Systems is trying something different, and getting paid for it now.
The Bristol startup has closed the first tranche of a £23mn Series A led by Mercia Ventures. The round takes its total funding past £28mn.
The money will scale production of radioactive isotopes used to diagnose and treat cancer. It is a market with a fragile supply chain and almost no UK source.
Tees River, Daphni and Blast Club joined the round. Returning backers Speedinvest and Playfair also took part, in a strong year for UK venture funding.The 💜 of EU techThe latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!
